Your session is about to expire
← Back to Search
Treatment for Pericarditis (RESONANCE Trial)
N/A
Recruiting
Research Sponsored by Kiniksa Pharmaceuticals (UK), Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights
No Placebo-Only Group
Summary
The registry will focus on furthering the understanding of the natural history of recurrent pericarditis (RP), as well as document RP-related clinical, health-related quality of life (HRQoL), and economic burden and will assist the medical community to refine or develop data-driven recommendations for clinical management of RP patients to optimize clinical outcomes. It also aims to generate data in support of the impact of rilonacept on clinical outcomes in a real-world population.
Eligible Conditions
- Pericarditis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Patients using 1 or more RP treatments
Secondary study objectives
Adverse event rate
Change in C-reactive protein (CRP)
Change in Multidetector (cardiac) computed tomography (MDCT)
+22 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Find a Location
Who is running the clinical trial?
Kiniksa Pharmaceuticals (UK), Ltd.Lead Sponsor
2 Previous Clinical Trials
112 Total Patients Enrolled
2 Trials studying Pericarditis
112 Patients Enrolled for Pericarditis
John F Paolini, MD, PhDStudy DirectorKiniksa Pharmaceuticals Corp
Dana Martin, PharmDStudy DirectorKiniksa Pharmaceuticals Corp
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger